|
A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma. |
|
|
Consulting or Advisory Role - Daiichi Sankyo |
Research Funding - Novartis |
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Consulting or Advisory Role - Adaptimmune; Deciphera; Tempus |
Research Funding - Adaptimmune (Inst); Athenex (Inst); Deciphera (Inst); Incyte (Inst); Merck (Inst) |
|
|
Honoraria - Daiichi Sankyo; Eisai; Lilly; Novartis; Roche |
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo; Eisai |
Research Funding - Eisai; Epizyme |
Travel, Accommodations, Expenses - Eisai; Roche |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche/Genentech |
Speakers' Bureau - Abbvie; Ignyta; Novartis |
Research Funding - MSD Oncology (Inst) |
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche |
|
|
Employment - Texas Oncology |
|
|
Honoraria - Amgen; Eisai; Lilly; Merck Sharp & Dohme |
Consulting or Advisory Role - Lilly; Lilly; Merck Sharp & Dohme |
Research Funding - Athenex (Inst); Deciphera (Inst); Efficient Pharma Management Corp. (Inst); Eisai (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiwan Liposome (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche |
|
|
Employment - Aptus Clinical; Athenex; Carrick Therapeutics; Cumulus Oncology; Inventiva Pharma; Octimet |
Stock and Other Ownership Interests - Carrick Therapeutics; Octimet |
|
|
|
Stock and Other Ownership Interests - Athenex; Merck Sharp & Dohme |
|
|
|
|
Stock and Other Ownership Interests - Athenex; GlaxoSmithKline; Merck/Schering Plough; Vertex |
Patents, Royalties, Other Intellectual Property - Multiple patents hold as employee of Athenex Inc, no royalties from any. |
Travel, Accommodations, Expenses - Athenex |
|
|
No Relationships to Disclose |